Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,380 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,984 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01503229 | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | completed | Phase 2 | 38 | Io TherapeuticsINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT00087165 |
| GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer |
| completed |
| Phase 2 |
| 22 |
| University Health Network, TorontoOTHER |
| 1 |
| Apr 28, 2021 |
| clinicaltrials |
| NCT01868386 | Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate(HypoFX) | completed | Phase 1 / Phase 2 | 32 | Timothy Showalter, MDOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02046837 | An Exercise Trial and Economic Analysis in Men With Prostate Cancer(ADT Ex RCT) | completed | Phase 2 | 59 | University Health Network, TorontoOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00350051 | ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer | completed | Phase 2 | 53 | BayerINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT00737893 | Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy(ERECT) | completed | Phase 2 | 56 | Johns Hopkins UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01317199 | Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02142608 | A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Bracco Diagnostics, IncINDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT01615120 | Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer | completed | Phase 2 | 77 | GTxINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01748500 | Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 21 | University Health Network, TorontoOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03179410 | PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer(PICK-NEPC) | completed | Phase 2 | 15 | Andrew J. Armstrong, MDOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT03263780 | High Resolution PET-MRI Before Prostate Cancer HIFU | completed | Phase 2 | 21 | Timothy J. DaskivichOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02628041 | HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer(HDRvsLDR) | completed | Phase 2 | 30 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT01341652 | Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer | completed | Phase 2 | 99 | University of Wisconsin, MadisonOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03418324 | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | completed | Phase 2 | 11 | Cedars-Sinai Medical CenterOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT02611882 | Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients(PSMA PET) | completed | Phase 2 | 225 | Thomas HopeOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT03348527 | A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer | completed | Phase 2 | 61 | Lidds ABINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT02919111 | Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients(PSMA PreRP) | completed | Phase 2 / Phase 3 | 299 | University of California, San FranciscoOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01940276 | Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer | completed | Phase 2 | 100 | Duke UniversityOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01051570 | Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel | completed | Phase 2 | 26 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT00428714 | Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy | completed | Phase 2 | 73 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02397408 | 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer | completed | Phase 2 | 18 | University of California, San FranciscoOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02036060 | Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.(ABIDO) | completed | Phase 2 | 119 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT01576172 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 159 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2020 | clinicaltrials |
| NCT00466440 | A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | completed | Phase 2 | 108 | Eli Lilly and CompanyINDUSTRY | 3 | Nov 6, 2020 | clinicaltrials |
| NCT00970203 | Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer | completed | Phase 2 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02199197 | Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer | completed | Phase 2 | 49 | University of UtahOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00006365 | External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 138 | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 22, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03515577 | Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery(PSMA vs AXUMIN) | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03675451 | PSMA Imaging of Localized Prostate Cancer | completed | Phase 2 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02064582 | Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer | completed | Phase 2 | 7 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT01875250 | Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02059213 | A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer | completed | Phase 2 | 72 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01931046 | Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 28 | Momotaro-Gene Inc.INDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT00049257 | Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 58 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT00514540 | Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer | completed | Phase 2 | 121 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01637402 | A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | completed | Phase 2 | 41 | Terence Friedlander, MDOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT00091390 | Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer | completed | Phase 2 | 129 | Radiation Therapy Oncology GroupNETWORK | 1 | Aug 10, 2020 | clinicaltrials |
| NCT02125357 | Sequencing Abiraterone and Enzalutamide in mCRPC | completed | Phase 2 | 202 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT00054574 | Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00087035 | Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer | completed | Phase 2 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT03362359 | Ga-68-PSMA-11 in High-risk Prostate Cancer | completed | Phase 1 / Phase 2 | 173 | German Cancer Research CenterOTHER | 2 | Jul 27, 2020 | clinicaltrials |
| NCT00460031 | Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 34 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03493997 | Multicentre International STudy for the Prevention With Ialuril® of Radio-induced Cystitis (MISTIC)(MISTIC) | completed | Phase 2 | 100 | Study Group for Urogenital Diseases, ItalyOTHER | 4 | Jul 23, 2020 | clinicaltrials |
Data updated 24 days agoSource updated May 14, 2021source: clinicaltrials